1-[2-(2-Chloro-phenoxy)-ethyl]-1H-benzoimidazol-2-ylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-[2-(2-Chloro-phenoxy)-ethyl]-1H-benzoimidazol-2-ylamine
• 英文别名: 1-[2-(2-chlorophenoxy)ethyl]benzimidazol-2-amine
• 化学式: C₁₅H₁₄ClN₃O
• mdl: MFCD01238024
• 分子量: 287.74
• InChiKey: UPDYFODQZAARMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  53.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF<br/>[FR] BENZIMIDAZOLES ET AZA-BENZIMIDAZOLES ET LEURS MÉTHODES D'UTILISATION
  申请人：GOLDFINCH BIO INC

  公开号：WO2019028308A1

  公开（公告）日：2019-02-07

  Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II). (Formulae (II), (III))

  根据公式（I）或（II）披露了化合物，以及包含它们的药物组合物。还披露了治疗方法，例如使用公式（I）或（II）的化合物治疗肾脏疾病。（公式（II），（III））
• Method for treating a chronic itch condition by administering small molecule MrgprX4 antagonists
  申请人：The Johns Hopkins University

  公开号：US11442059B2

  公开（公告）日：2022-09-13

  The present invention relates to cells and methods for detecting compounds that affect G protein coupled receptor mediated conditions. The invention also relates to methods for treating adverse drug reactions, autoimmune disorders, and pruritus.

  本发明涉及检测影响 G 蛋白偶联受体介导情况的化合物的细胞和方法。本发明还涉及治疗药物不良反应、自身免疫性疾病和瘙痒症的方法。
• COMPOSITIONS AND METHODS FOR TREATING G PROTEIN COUPLED RECEPTOR MEDIATED CONDITIONS
  申请人：The Johns Hopkins University

  公开号：US20200173985A1

  公开（公告）日：2020-06-04

  The present invention relates to cells and methods for detecting compounds that affect G protein coupled receptor mediated conditions. The invention also relates to methods for treating adverse drug reactions, autoimmune disorders, and pruritus.
• BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF
  申请人：Goldfinch Bio., Inc.

  公开号：US20200377505A1

  公开（公告）日：2020-12-03

  Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II).